Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, FVT

HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ON FEBRUARY 22, 2024


PLYMOUTH MEETING, Pa., Feb. 8, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2023 financial results on Thursday, February 22, 2024, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on February 22, 2024, at 8:30 a.m. ET to discuss the results.

To participate in the call, please dial (800) 579-2543 (domestic) or +1 (785) 424-1789 (international), and reference passcode HRMYQ423. It is recommended that you dial in at least 10 minutes prior to the call.

The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
[email protected]

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
[email protected]

SOURCE Harmony Biosciences


These press releases may also interest you

at 10:30
GenomOncology Introduces Expanded Support for Germline Testing in GO Pathology Workbench
GenomOncology (GO) revealed today an upgraded version of GO Pathology Workbench, their software platform for tertiary analysis and reporting of next generation sequencing (NGS) and other molecular testing results. This version includes expanded...

at 10:30
Cancer Biomarkers Market Worth $42.0 billion | MarketsandMarketstm
Cancer Biomarkers Market in terms of revenue was estimated to be worth $24.5 billion in 2024 and is poised to reach $42.0 billion by 2029, growing at a CAGR of 11.3% from 2024 to 2029 according to a new report by MarketsandMarketstm. Increasing...

at 10:30
Global Plant Stem Cell Skincare Product Market to reach a Valuation of US$ 353.9 million by 2034 | Future Market Insights, Inc.
Future Market Insights (FMI) predicts a surge in the plant stem cell skincare product market. This growth is primarily driven by rising consumer demand for multi-benefit skincare solutions. Consumers are increasingly seeking products that offer...

at 10:25
Cold Box Express, Inc. Introduces Refreshed Brand, New Website to Better Define Offering
Cold Box Express, Inc. (CBX) has announced a rebranding of both the company and its product the ClimateCratetm (formerly COLD BOX). While the corporate company name remains Cold Box Express, Inc., the evolution to CBX simplifies the logo and helps...

at 10:20
Todd Clegg Named Carestream's Chief Executive Officer
Carestream, a world-leading provider of medical imaging systems and non-destructive testing solutions, announced that Todd Clegg has been named CEO and appointed to the Board of Directors, effective immediately. Mr. Clegg joined Carestream in...

at 10:19
FDA Takes Action Aimed at Helping to Ensure the Safety and Effectiveness of Laboratory Developed Tests
Today, the U.S. Food and Drug Administration took action aimed at helping to ensure the safety and effectiveness of laboratory developed tests, or LDTs, which are used in a growing number of health care decisions and about which concerns have been...

More news about Health...


News published on and distributed by: